載入...
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma
Traditionally, overall survival (os) has been considered the “gold standard” for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However, as the available options for continuing therapy in...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Multimed Inc.
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3176905/ https://ncbi.nlm.nih.gov/pubmed/21969807 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|